Down-regulation of cytochrome P450 proteins and its activities by Shiga-like toxin II from Escherichia coli O157:H7

Biochemical Pharmacology

Volumn 67, Issue 8, 2004, Pages 1427-1435

  Kitaichi, Kiyoyuki ^a   Nakayama, Hironao ^a   Ueyama, Jun ^a   Nadai, Masayuki ^b   Baba, Kenji ^c   Takagi, Kenji ^a   Takagi, Kenzo ^a   Ohta, Michio ^d   Hasegawa, Takaaki ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b MEIJO UNIVERSITY   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP; Cytochrome P450; DEX; Dexamethasone; L NAME; Lipopolysaccharide; LPS; N nitro L arginine methyl ester; Nitric oxide; Nitric oxide synthase; NO; NOS; S methylisothiourea; Shiga like toxin; SLT; SLT II; SMT; TNF ; Tumor necrosis factor

Indexed keywords

CYTOCHROME P450 2C11; CYTOCHROME P450 3A2; DEXAMETHASONE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIVER ENZYME; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHENAZONE; S METHYLPSEUDOTHIOUREA; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; VEROTOXIN 2;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ESCHERICHIA COLI; IN VIVO STUDY; INJECTION; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; TIME;

ANIMALS; ANTIPYRINE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; DOWN-REGULATION; DRUG INTERACTIONS; ESCHERICHIA COLI O157; ISOTHIURONIUM; LIVER; MALE; MEMBRANE PROTEINS; NITRIC OXIDE; RATS; RATS, WISTAR; SHIGA-LIKE TOXIN II; STEROID 16-ALPHA-HYDROXYLASE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1642298805     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.12.009     Document Type: Article

References (57)

1. O'Loughlin E.V., Robins-Browne R.M. Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells. Microbes Infect. 3:2001;493-507.
2. O'Brien A.D., Tesh V.L., Donohue-Rolfe A., Jackson M.P., Olsnes S., Sandvig K., Lindberg A.A., Keusch G.T. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 180:1992;65-94.
3. Johannes L. The epithelial cell cytoskeleton and intracellular trafficking. I. Shiga toxin B-subunit system: retrograde transport, intracellular vectorization, and more. Am. J. Physiol. Gastrointest. Liver Physiol. 283:2002;G1-G7.
4. Sandvig K., Grimmer S., Lauvrak S.U., Torgersen M.L., Skretting G., van Deurs B., Iversen T.G. Pathways followed by ricin and Shiga toxin into cells. Histochem. Cell Biol. 117:2002;131-141.
5. Tesh V.L. Shiga toxins - not just cytotoxins anymore. Trends Microbiol. 9:2001;584-585.
6. Hughes A.K., Stricklett P.K., Kohan D.E. Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells. Kidney Int. 54:1998;426-437.
7. Lingwood C.A. Verotoxin-binding in human renal sections. Nephron. 66:1994;21-28.
8. Tesh V.L., Burris J.A., Owens J.W., Gordon V.M., Wadolkowski E.A., O'Brien A.D., Samuel J.E. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect. Immun. 61:1993;3392-3402.
9. Carter A.O., Borczyk A.A., Carlson J.A., Harvey B., Hockin J.C., Karmali M.A., Krishnan C., Korn D.A., Lior H. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N. Engl. J. Med. 317:1987;1496-1500.
10. Wong C.S., Jelacic S., Habeeb R.L., Watkins S.L., Tarr P.I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342:2000;1930-1936.
11. Tapper D., Tarr P., Avner E., Brandt J., Waldhausen J. Lessons learned in the management of hemolytic uremic syndrome in children. J. Pediatr. Surg. 30:1995;158-163.
12. Zhao Y.L., Cen X.B., Ito M., Yokoyama K., Takagi K., Kitaichi K., Nadai M., Ohta M., Takagi K., Hasegawa T. Shiga-like toxin II derived from Escherichia coli O157:H7 modifies renal handling of levofloxacin in rats. Antimicrob. Agents Chemother. 46:2002;1522-1528.
13. Hasegawa T., Takagi K., Kitaichi K. Effects of bacterial endotoxin on drug pharmacokinetics. Nagoya J. Med. Sci. 62:1999;11-28.
14. Hidemura K., Zhao Y.L., Ito K., Nakao A., Tatsumi Y., Kanazawa H., Takagi K., Ohta M., Hasegawa T. Shiga-like toxin II impairs hepatobiliary transport of doxorubicin in rats by down-regulation of hepatic P glycoprotein and multidrug resistance-associated protein Mrp2. Antimicrob. Agents Chemother. 47:2003;1636-1642.
15. Foster G.H., Armstrong C.S., Sakiri R., Tesh V.L. Shiga toxin-induced tumor necrosis factor alpha expression: requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases. Infect. Immun. 68:2000;5183-5189.
16. Ramegowda B., Tesh V.L. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect. Immun. 64:1996;1173-1180.
17. Thorpe C.M., Hurley B.P., Lincicome L.L., Jacewicz M.S., Keusch G.T., Acheson D.W. Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells. Infect. Immun. 67:1999;5985-5993.
18. Thorpe C.M., Smith W.E., Hurley B.P., Acheson D.W. Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect. Immun. 69:2001;6140-6147.
19. van Setten P.A., Monnens L.A., Verstraten R.G., van den Heuvel L.P., van Hinsbergh V.W. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood. 88:1996;174-183.
20. Yuhas Y., Kaminsky E., Mor M., Ashkenazi S. Induction of nitric oxide production in mouse macrophages by Shiga toxin. J. Med. Microbiol. 45:1996;97-102.
21. Andes D., Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents. 19:2002;261-268.
22. Kitaichi K., Wang L., Takagi K., Iwase M., Shibata E., Nadai M., Hasegawa T. Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide. Antimicrob. Agents Chemother. 43:1999;2697-2701.
23. Nadai M., Hasegawa T., Kato K., Wang L., Nabeshima T., Kato N. Alterations in pharmacokinetics and protein binding behavior of cefazolin in endotoxemic rats. Antimicrob. Agents Chemother. 37:1993;1781-1785.
24. Nadai M., Hasegawa T., Kato K., Wang L., Nabeshima T., Kato N. Influence of a bacterial lipopolysaccharide on the pharmacokinetics of tobramycin in rats. J. Pharm. Pharmacol. 45:1993;971-974.
25. Nadai M., Sekido T., Matsuda I., Li W., Kitaichi K., Itoh A., Nabeshima T., Hasegawa T. Time-dependent effects of Klebsiella pneumoniae endotoxin on hepatic drug-metabolizing enzyme activity in rats. J. Pharm. Pharmacol. 50:1998;871-879.
26. Engel G., Hofmann U., Heidemann H., Cosme J., Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3- hydroxymethylantipyrine, and norantipyrine formation. Clin. Pharmacol. Ther. 59:1996;613-623.
27. Souček P., Gut I. Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica. 22:1992;83-103.
28. Manuel P. The CYP3A family. In: Ioannides C, editor. Cyrochrome P450: metabolic and toxicological aspects, Chapter 10. London, UK: R.B. Stern; 1996. p. 241-70.
29. Morgan E.T. Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev. 29:1997;1129-1188.
30. Gergel D., Misik V., Riesz P., Cederbaum A.I. Inhibition of rat and human cytochrome P4502E1 catalytic activity and reactive oxygen radical formation by nitric oxide. Arch. Biochem. Biophys. 337:1997;239-250.
31. Khatsenko O., Kikkawa Y. Nitric oxide differentially affects constitutive cytochrome P450 isoforms in rat liver. J. Pharmacol. Exp. Ther. 280:1997;1463-1470.
32. Minamiyama Y., Takemura S., Imaoka S., Funae Y., Tanimoto Y., Inoue M. Irreversible inhibition of cytochrome P450 by nitric oxide. J. Pharmacol. Exp. Ther. 283:1997;1479-1485.
33. Wink D.A., Osawa Y., Darbyshire J.F., Jones C.R., Eshenaur S.C., Nims R.W. Inhibition of cytochromes P450 by nitric oxide and a nitric oxide-releasing agent. Arch. Biochem. Biophys. 300:1993;115-123.
34. Khatsenko O.G., Gross S.S., Rifkind A.B., Vane J.R. Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc. Natl. Acad. Sci. U.S.A. 90:1993;11147-11151.
35. Szabo C., Southan G.J., Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 91:1994;12472-12476.
36. Zhao Y.L., Du J., Kanazawa H., Cen X.B., Takagi K., Kitaichi K., Tatsumi Y., Takagi K., Ohta M., Hasegawa T. Shiga-like toxin II modifies brain distribution of a P-glycoprotein substrate, doxorubicin, and P-glycoprotein expression in mice. Brain Res. 956:2002;246-253.
37. Fischer E., Gregus Z., Varga F. Effects of barbiturates on the hepatic cytochrome P-450 dependent enzyme system and biliary excretion of exogenous organic anions in rats. Digestion. 20:1980;115-120.
38. Wang D., Wei J., Hsu K., Jau J., Lieu M.W., Chao T.J., Chen H.I. Effects of nitric oxide synthase inhibitors on systemic hypotension, cytokines and inducible nitric oxide synthase expression and lung injury following endotoxin administration in rats. J. Biomed. Sci. 6:1999;28-35.
39. Sacco S., Agnello D., Sottocorno M., Lozza G., Monopoli A., Villa P., Ghezzi P. Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats. J. Neurochem. 71:1998;2063-2070.
40. Pilsgaard H., Poulsen H.E. A one-sample method for antipyrine clearance determination in rats. Pharmacology. 29:1984;110-116.
41. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 239:1964;2370-2378.
42. LaCasse E.C., Bray M.R., Patterson B., Lim W.M., Perampalam S., Radvanyi L.G., Keating A., Stewart A.K., Buckstein R., Sandhu J.S., Miller N., Banerjee D., Singh D., Belch A.R., Pilarski L.M., Gariepy J. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood. 94:1999;2901-2910.
43. Meyers K.E., Kaplan B.S. Many cell types are Shiga toxin targets. Kidney Int. 57:2000;2650-2651.
44. Ghezzi P., Saccardo B., Villa P., Rossi V., Bianchi M., Dinarello C.A. Role of interleukin-1 in the depression of liver drug metabolism by endotoxin. Infect. Immun. 54:1986;837-840.
45. Kurokohchi K., Yoneyama H., Matsuo Y., Nishioka M., Ichikawa Y. Effects of interleukin 1 alpha on the activities and gene expressions of the cytochrome P450IID subfamily. Biochem. Pharmacol. 44:1992;1669-1674.
46. Morgan E.T., Thomas K.B., Swanson R., Vales T., Hwang J., Wright K. Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver. Biochim. Biophys. Acta. 1219:1994;475-483.
47. Wright K., Morgan E.T. Regulation of cytochrome P450IIC12 expression by interleukin-1 alpha, interleukin-6, and dexamethasone. Mol. Pharmacol. 39:1991;468-474.
48. Donato M.T., Guillen M.I., Jover R., Castell J.V., Gomez-Lechon M.J. Nitric oxide-mediated inhibition of cytochrome P450 by interferon-gamma in human hepatocytes. J. Pharmacol. Exp. Ther. 281:1997;484-490.
49. Hodgson P.D., Renton K.W. The role of nitric oxide generation in interferon-evoked cytochrome P450 down-regulation. Int. J. Immunopharmacol. 7:1995;995-1000.
50. Nadin L., Butler A.M., Farrell G.C., Murray M. Pretranslational down-regulation of cytochromes P450 2C11 and 3A2 in male rat liver by tumor necrosis factor alpha. Gastroenterology. 109:1995;198-205.
51. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:1991;109-142.
52. Bitzan M.M., Wang Y., Lin J., Marsden P.A. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J. Clin. Invest. 101:1998;372-382.
53. Dran G.I., Fernandez G.C., Rubel C.J., Bermejo E., Gomez S., Meiss R., Isturiz M.A., Palermo M.S. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Kidney Int. 62:2002;1338-1348.
54. Kita Y., Hirasawa Y., Fukuyama S., Ohkubo K., Kato Y., Takamatsu H., Ohno M., Nishino S., Kato M., Seki J. Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners. J. Pharmacol. Exp. Ther. 276:1996;421-425.
55. Eeckhoudt S.L., Horsmans Y., Verbeeck R.K. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica. 32:2002;975-984.
56. Ronis M.J., Rowlands J.C., Hakkak R., Badger T.M. Altered expression and glucocorticoid-inducibility of hepatic CYP3A and CYP2B enzymes in male rats fed diets containing soy protein isolate. J. Nutr. 129:1999;1958-1965.
57. Yokogawa K., Shimada T., Higashi Y., Itoh Y., Masue T., Ishizaki J., Asahi M., Miyamoto K. Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. Biochem. Pharmacol. 63:2002;777-783.